Semaglutide Use in Elderly Patients with Diabetic Retinopathy

Key Considerations

The American College of Cardiology recommends that semaglutide be used with caution in patients with stable diabetic retinopathy, particularly in those over 60 years old, due to the documented risk of retinopathy complications 1, 2
Semaglutide carries a specific warning for diabetic retinopathy complications that is not consistently observed with other GLP-1RAs, predominantly seen in patients with prior history of proliferative retinopathy 1, 2, 3
The risk of retinopathy complications with semaglutide is hypothesized to result from rapid and sustained reductions in blood glucose rather than a direct drug effect 1, 3

Before starting semaglutide, patients must have a recent comprehensive ophthalmologic examination to document current retinopathy status, and an assessment of renal function (eGFR) 1, 4
Patients should also be assessed for personal or family history of medullary thyroid cancer or MEN2, and evaluated for pancreatitis history and gastroparesis symptoms 3, 5

The American College of Cardiology recommends starting semaglutide at the lowest dose and titrating slowly to minimize GI side effects and rapid glycemic changes that may worsen retinopathy 3, 6
The initiation protocol should include weekly dose increments, starting with 0.25 mg subcutaneously once weekly, and increasing to 0.5 mg, 1.0 mg, and 1.7 mg as tolerated 3, 6

During the first 4-8 weeks of semaglutide treatment, patients should be closely monitored for home glucose levels, especially if on insulin, sulfonylureas, or glinides 7
Patients should also be monitored for GI symptoms, such as nausea, vomiting, and diarrhea, and assessed for volume depletion and signs of pancreatitis 1, 3

In elderly patients, semaglutide use requires additional caution due to the higher risk of volume depletion, orthostatic hypotension, and increased fall risk from dizziness or hypoglycemia 1, 3
Elderly patients should be instructed to hold medication if unable to maintain hydration during nausea episodes, and polypharmacy concerns should be addressed due to potential delayed gastric emptying and affected absorption of other medications 5, 6, 7

The American College of Cardiology recommends reducing the total daily dose of insulin by 20% immediately to prevent hypoglycemia in patients taking semaglutide 8
The American College of Cardiology suggests discontinuing or reducing the dose of sulfonylureas by 50% in patients taking semaglutide to prevent hypoglycemia 8
The American College of Cardiology advises considering discontinuing other insulin secretagogues, such as meglitinides, in patients taking semaglutide 8
Patients with gastroparesis or severe GI motility disorders should avoid using semaglutide, as recommended by the American College of Cardiology 8
Patients with active gallbladder disease should avoid using semaglutide, according to the American College of Cardiology 8

The American College of Cardiology recommends that patients monitor their blood glucose at home for the first 4 weeks, especially before meals and at bedtime, when taking semaglutide 8
Mitigation strategies for gastrointestinal symptoms, such as starting at the lowest dose, eating smaller portions, and avoiding high-fat foods, are recommended by the American College of Cardiology 8
The American College of Cardiology suggests establishing a monitoring plan, including home glucose monitoring and assessing GI tolerance, especially during the first 4 weeks of semaglutide treatment 8

The American College of Cardiology advises avoiding the use of semaglutide in patients with a history of pancreatitis, as it has not been studied in this population, and in patients with diabetic retinopathy, kidney disease, or thyroid cancer, closer monitoring is required 8

A comprehensive ophthalmologic examination is recommended by the American College of Cardiology before continuing semaglutide treatment, especially in patients with diabetes or over 60 years old 8